Table 5 |
||
|
HMG-CoA reductase activity in hamster hepatic microsomes (pmol [14C]mevalonolactone/min/mg microsomal protein) |
||
|
Group |
Activity-NaF |
Total activity+NaF |
|
|
||
|
Control |
12.36 |
9.30 |
|
Lovastatin |
13.34 |
ND |
|
Gl (2.5%) |
5.86a |
2.66a |
|
Gl (5%) |
8.08a |
4.86a |
|
|
||
|
Refer to the text for methodologic details. [14C]mevalonate was converted to [14C]mevalonolactone with 10 M HCl before the TLC step. Values above were corrected for recovery (15–63%) with [3H]mevalonate. G. lucidum, but not lovastatin, was found to inhibit ex vivo synthesis whether: recovery was accounted for; results were expressed per gram liver weight; [14C]mevalonolactone was first extracted into organic solvent and then applied to TLC plates [79] rather than applying aqueous extracts directly to TLC plates [55] as reported above (data not shown); and whether or not endogenous phosphatase activity was inhibited with 50 mM NaF (shown above). Values represent mean of 6 determinations. aSignificantly different from control, students unpaired, 2-tailed t-test, equal variances (P < 0.05). ND, not determined. |
||
|
Berger et al. Lipids in Health and Disease 2004 3:2 doi:10.1186/1476-511X-3-2 |
||